Setback: Biogen loses bid to revive patent on Mylan blockbuster MS drug Tecfidera

Tecfidera, on the market since 2013, has been key to Biogen's fortunes while it struggles to find new medicines to make up for declining revenue.

Related Keywords

Delaware ,United States ,Cambridge ,Cambridgeshire ,United Kingdom ,Washington ,Massachusetts ,West Virginia ,Kathleen Omalley ,Brian Abrahams ,Jimmie Reyna ,Biogen International Gmb ,Drug Administration ,Us Court ,Biogen Ma Inc ,Viatris Inc ,Shilpa Medicare Ltd ,Cadila Healthcare Ltd ,Mylan Pharmaceuticals Inc ,Federal Circuit ,Judge Jimmie Reyna ,Patent Trial ,Appeal Board ,Shilpa Medicare ,Judge Kathleeno Malley ,Want Biogen ,Someone Has ,Mylan Pharmaceuticals ,Biogen International Gmbh ,Pharmaceuticals Inc ,Patent ,Pharma ,Biogen ,Biogen News ,Multiple Sclerosis ,Tecfidera ,Mylan ,Viatris ,Novartis ,Sandoz ,Cadila Healthcare ,Aducanumab , ,